MedPath

Monte Rosa Therapeutics

🇺🇸United States
Ownership
Public
Employees
133
Market Cap
$415.4M
Website
http://www.monterosatx.com

Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025

Monte Rosa Therapeutics anticipates 2025 milestones, including Q1 clinical data for MRT-2359 in MYC-driven tumors and MRT-6160 for autoimmune diseases, with a $377M cash position funding operations into 2028. MRT-8102 IND filing expected H1 2025, alongside advancements in CDK2 and NEK7 programs.
geneonline.com
·

Biotech Giants Behind Partnerships in Precision Therapies, Gene Editing, and ADCs

2024 saw biotech giants like Roche, Merck, and Biogen forming partnerships to advance precision therapies, gene editing, and ADCs. Roche collaborated with Dyno Therapeutics for AI-driven gene therapies, while Merck invested $4 billion in ADCs. The global ADC market is projected to grow significantly, driven by innovations in cancer treatment. Strategic M&A activities aimed at expanding pipelines in oncology, immunology, and rare diseases, highlighting a shift towards innovative, targeted therapies.
globenewswire.com
·

Targeted Protein Degradation Industry Forecast to Reach

The global targeted protein degradation market is projected to grow from USD 0.548 billion in 2023 to USD 4.37 billion by 2034, driven by precision medicine, drug discovery investments, and technological advancements. PROTACs lead the market, with molecular glues expected to grow fastest. Therapy development dominates applications, particularly in cancer and neurodegenerative diseases. Pharmaceutical & biotechnology companies are the largest end-users. North America leads in revenue, while Asia-Pacific shows the highest growth rate.
icr.ac.uk
·

Precision oncology company Sentinal4D completes pre-seed funding round and launches

Sentinal4D, a spinout from The Institute of Cancer Research, London, has closed its first funding round and appointed its leadership team. The company aims to accelerate drug discovery in oncology using AI-driven personalized therapeutics. Founded by Georgia Mitsi, Chris Bakal, and Matt de Vries, Sentinal4D leverages high-throughput 3D imaging and proprietary AI models to predict drug efficacy and patient response. Supported by Twin Path Ventures, Arben Ventures, and angel investors, Sentinal4D seeks to transform drug development with a biology-first strategy.
biospace.com
·

Molecular Glue Degraders at Inflection Point as Pharma Dives In

Molecular glue degraders, discovered serendipitously, have opened a new field of drug discovery, attracting Big Pharma investments. These small molecules enhance protein destruction by interacting with ligases, targeting 'undruggable' proteins. Major deals in 2024 include collaborations between Biogen, Novartis, Takeda, and Novo Nordisk, potentially worth over $6 billion. The therapeutic potential spans oncology, neurodegeneration, autoimmune, and cardiometabolic diseases. The discovery of cereblon as thalidomide's target in 2010 was pivotal, leading to further research and development in this space.
quantisnow.com
·

Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors

Monte Rosa Therapeutics appoints Eric A. Hughes, M.D, Ph.D., to its Board of Directors. Dr. Hughes, currently EVP, Global R&D and CMO of Teva Pharmaceuticals, brings extensive biopharmaceutical experience. Monte Rosa develops molecular glue degrader (MGD) medicines, leveraging its QuEEN discovery engine for oncology, autoimmune, and inflammatory diseases.
globenewswire.com
·

NLRP3 Protein Inhibitors Clinical Trial Pipeline Appears

NLRP3 protein inhibitors show promise in treating autoimmune, inflammatory, neurodegenerative, and metabolic diseases. Over 20 pharma companies are developing 25+ inhibitors, with notable progress in clinical trials by Halia Therapeutics, Ventus Therapeutics, and Novo Nordisk.
prnewswire.com
·

75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space

DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report highlights 75+ companies developing 80+ therapies, including promising candidates like GA Depot, Remibrutinib, and IMU 838. Key events include Immunic's positive Phase 3 ENSURE trial interim analysis, Roche's FDA approval for Ocrevus injectable, and Sanofi's mixed results for tolebrutinib in Phase III trials. The report covers global pipeline stages, product types, molecule types, mechanisms of action, and routes of administration.
biospace.com
·

Biogen Tops Wall Street Expectations for Leqembi, Inks Molecular Glue Deal

Biogen's Q3 revenue exceeded expectations, with Leqembi sales rising to $67M. The company raised its EPS guidance to $16.10-$16.60. Biogen's MS drug sales declined, but new product launches are expected to offset this. The firm also partnered with Neomorph for molecular glue degrader development and decided not to pursue MDD for Zurzuvae.
© Copyright 2025. All Rights Reserved by MedPath